Careers  |  Sign In  |  Register

Managing ALK-Positive NSCLC Disease Progression

In this double interview, Ross Camidge, MD, PhD, of the University of Colorado Cancer Center, and Lyudmila A. Bazhenova, MD, of UC San Diego Health, provide insights into ALK-positive non-small cell lung cancer treatments and their relationships to disease progression in the body and associated brain metastases. They also discuss their treatment approaches when deciding to switch therapies because of disease progression or observed toxicities.

Read the full transcript by clicking here.